Expression of a Synthetic Staphylococcal Enterotoxin B in Escherichia coli BL21(DE3) for Cancer Therapy Development

Achmad Rodiansyah, Marselina Irasonia Tan, Husna Nugrahapraja

Abstract


Staphylococcal enterotoxin B (SEB) from Staphylococcus aureus is a potential therapeutic agent for cancer. SEB can activate the immune response, which could induce apoptosis of various cancer cells. This study aimed to design and produce a recombinant SEB protein using Escherichia coli BL21(DE3) expression system. We designed and optimized the codon of the inserted gene for E. coli and then transformed it into E. coli BL21(DE3). The transformants were verified by selective media containing kanamycin followed by colony PCR with T7 promoter and T7 terminator primers and DNA sequencing. The results showed that the SEBsyn encoding gene could be synthesized and cloned into pET-28a(+) expression plasmid. This recombinant plasmid that carried the SEB encoding gene (pET-28a_SEBsyn) was successfully transformed into E. coli BL21(DE3). The amplicons of colony PCR visualized in 2% agarose gel showed that transformants carrying the recombinant plasmid had an inserted gene length of about 1 kb. Gene inserts sequence verification by DNA sequencing resulted in 1,148 bp sequence consensus. The blastx analysis showed that it had the best hit with enterotoxin B in the NCBI database (accession id CAC6284025.1). The recombinant SEB protein was also successfully overexpressed in E. coli BL21(DE3) with 0.1 mM IPTG. Our recombinant SEB protein was dominantly insoluble in the inclusion body; however, some SEB protein was expressed as soluble. The molecular weight of the target protein is about 29 kDa.

Keywords


Enterotoxin; cancer; Staphylococcal enterotoxin B; Staphylococcus aureus

Full Text:

PDF

References


H. Freisling et al., “Lifestyle factors and risk of multimorbidity of cancer and cardiometabolic diseases: A multinational cohort study,†BMC Med., vol. 18, no. 1, pp. 1–11, 2020, doi: 10.1186/s12916-019-1474-7.

J. Jin et al., “Identification of genetic mutations in cancer: Challenge and opportunity in the new era of targeted therapy,†Front. Oncol., vol. 9, no. MAR, pp. 1–7, 2019, doi: 10.3389/fonc.2019.00263.

A. Eckerling, I. Ricon-Becker, L. Sorski, E. Sandbank, and S. Ben-Eliyahu, “Stress and cancer: mechanisms, significance and future directions,†Nat. Rev. Cancer, vol. 21, no. 12, pp. 767–785, 2021, doi: 10.1038/s41568-021-00395-5.

H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,†CA. Cancer J. Clin., vol. 71, no. 3, pp. 209–249, 2021, doi: 10.3322/caac.21660.

Globocan, “360-Indonesia-fact-sheet,†2020. [Online]. Available: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf.

M. C. Best et al., “Patient perspectives on molecular tumor profiling: ‘why wouldn’t you?,’†BMC Cancer, vol. 19, no. 1, pp. 1–9, 2019, doi: 10.1186/s12885-019-5920-x.

G. S. Karagiannis, J. S. Condeelis, and M. H. Oktay, “Chemotherapy-induced metastasis: Molecular mechanisms, clinical manifestations, therapeutic interventions,†Cancer Res., vol. 79, no. 18, pp. 4567–4577, 2019, doi: 10.1158/0008-5472.CAN-19-1147.

N. Ortiz-Otero, J. R. Marshall, B. Lash, and M. R. King, “Chemotherapy-induced release of circulating-tumor cells into the bloodstream in collective migration units with cancer-associated fibroblasts in metastatic cancer patients,†BMC Cancer, vol. 20, no. 1, pp. 1–13, 2020, doi: 10.1186/s12885-020-07376-1.

R. S. Epstein et al., “Cancer patients’ perspectives and experiences of chemotherapy-induced myelosuppression and its impact on daily life,†Patient Prefer. Adherence, vol. 15, pp. 453–465, 2021, doi: 10.2147/PPA.S292462.

S. S. Arunachalam et al., “Study on knowledge of chemotherapy’s adverse effects and their self-care ability to manage - The cancer survivors impact,†Clin. Epidemiol. Glob. Heal., vol. 11, no. March, p. 100765, 2021, doi: 10.1016/j.cegh.2021.100765.

B. Prieto-Callejero et al., “Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer,†Medicine (Baltimore)., vol. 99, no. 33, p. e21695, 2020, doi: 10.1097/MD.0000000000021695.

M. Mansour, S. Ismail, and K. Abou-Aisha, “Bacterial delivery of the antitumor azurin-like protein Laz to glioblastoma cells,†AMB Express, vol. 10, no. 1, 2020, doi: 10.1186/s13568-020-00995-8.

D. Trivanović, K. Pavelić, and Ž. Peršurić, “Fighting Cancer with Bacteria and Their Toxins,†Int. J. Mol. Sci., vol. 22, no. 23, 2021, doi: 10.3390/ijms222312980.

M. Sedighi et al., “Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities,†Cancer Med., vol. 8, no. 6, pp. 3167–3181, 2019, doi: 10.1002/cam4.2148.

M. T. Q. Duong, Y. Qin, S. H. You, and J. J. Min, “Bacteria-cancer interactions: bacteria-based cancer therapy,†Exp. Mol. Med., vol. 51, no. 12, 2019, doi: 10.1038/s12276-019-0297-0.

X. Zhang, X. Hu, and X. Rao, “Apoptosis induced by Staphylococcus aureus toxins,†Microbiol. Res., vol. 205, no. April, pp. 19–24, 2017, doi: 10.1016/j.micres.2017.08.006.

K. E. J. Rödström, K. Elbing, and K. Lindkvist-Petersson, “Structure of the Superantigen Staphylococcal Enterotoxin B in Complex with TCR and Peptide–MHC Demonstrates Absence of TCR–Peptide Contacts,†J. Immunol., vol. 193, no. 4, pp. 1998–2004, 2014, doi: 10.4049/jimmunol.1401268.

P. Knopick et al., “Endogenous HLA-DQ8αβ programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival,†J. Immunother. Cancer, vol. 8, no. 2, 2020, doi: 10.1136/jitc-2020-001493.

D. Verreault et al., “Effective treatment of staphylococcal enterotoxin B aerosol intoxication in rhesus macaques by using two parenterally administered high-affinity monoclonal antibodies,†Antimicrob. Agents Chemother., vol. 63, no. 5, pp. 1–12, 2019, doi: 10.1128/AAC.02049-18.

D. M. Ranelli, C. L. Jones, M. B. Johns, G. J. Mussey, and S. A. Khan, “Molecular cloning of staphylococcal enterotoxin B gene in Escherichia coli and Staphylococcus aureus,†Proc. Natl. Acad. Sci. U. S. A., vol. 82, no. 17, pp. 5850–5854, 1985, doi: 10.1073/pnas.82.17.5850.

J. W. Dubendorf and F. W. Studier, “Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with lac repressor,†J. Mol. Biol., vol. 219, no. 1, pp. 45–59, 1991, doi: https://doi.org/10.1016/0022-2836(91)90856-2.

C. Ye, X. Chen, M. Yang, X. Zeng, and S. Qiao, “CRISPR/Cas9 mediated T7 RNA polymerase gene knock-in in E. coli BW25113 makes T7 expression system work efficiently,†J. Biol. Eng., vol. 15, no. 1, pp. 1–16, 2021, doi: 10.1186/s13036-021-00270-9.

P. J. Shilling, K. Mirzadeh, A. J. Cumming, M. Widesheim, Z. Köck, and D. O. Daley, “Improved designs for pET expression plasmids increase protein production yield in Escherichia coli,†Commun. Biol., vol. 3, no. 1, 2020, doi: 10.1038/s42003-020-0939-8.

M. J. Park, M. S. Park, and G. E. Ji, “Improvement of the electro-transformed cell yield for Bifidobacterium sp. With large DNA,†Korean J. Food Sci. Technol., vol. 51, no. 2, pp. 188–191, 2019, doi: 10.9721/KJFST.2019.51.2.188.

M. M. Islam et al., “Cell-Penetrating Peptide-Mediated Transformation of Large Plasmid DNA into Escherichia coli,†ACS Synth. Biol., vol. 8, no. 5, pp. 1215–1218, 2019, doi: 10.1021/acssynbio.9b00055.

Y. Wang et al., “Effects of Sr2+ on the preparation of Escherchia coli DH5α competent cells and plasmid transformation,†PeerJ, vol. 8, p. e9480, 2020.

S. B. Nouemssi, M. Ghribi, R. Beauchemin, F. Meddeb-Mouelhi, H. Germain, and I. Desgagné-Penix, “Rapid and efficient colony-pcr for high throughput screening of genetically transformed Chlamydomonas reinhardtii,†Life, vol. 10, no. 9, pp. 1–13, 2020, doi: 10.3390/life10090186.

M. R. Green and J. Sambrook, “Polymerase chain reaction,†Cold Spring Harb. Protoc., vol. 2019, no. 6, p. pdb--top095109, 2019.

Z. J. Johnson, D. D. Krutkin, P. Bohutskyi, and M. G. Kalyuzhnaya, “Metals and methylotrophy: Via global gene expression studies,†Methods Enzymol., vol. 650, pp. 185–213, Jan. 2021, doi: 10.1016/BS.MIE.2021.01.046.

C. Delahaye and J. Nicolas, “Sequencing DNA with nanopores: Troubles and biases,†PLoS One, vol. 16, no. 10 October, 2021, doi: 10.1371/journal.pone.0257521.

A. Alexaki et al., “Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies,†Sci. Rep., vol. 9, no. 1, 2019, doi: 10.1038/s41598-019-51984-2.

Y. Liu, “A code within the genetic code: Codon usage regulates co-translational protein folding,†Cell Commun. Signal., vol. 18, no. 1, pp. 1–9, 2020, doi: 10.1186/s12964-020-00642-6.

F. Xue et al., “Codon-Optimized Rhodotorula glutinis PAL Expressed in Escherichia coli With Enhanced Activities,†Front. Bioeng. Biotechnol., vol. 8, no. February, pp. 1–9, 2021, doi: 10.3389/fbioe.2020.610506.

J. Konczal, J. Bower, and C. H. Gray, “Re-introducing non-optimal synonymous codons into codon-optimized constructs enhances soluble recovery of recombinant proteins from Escherichia coli,†PLoS One, vol. 14, no. 4, pp. 1–17, 2019, doi: 10.1371/journal.pone.0215892.

H. Fu et al., “Codon optimization with deep learning to enhance protein expression,†Sci. Rep., vol. 10, no. 1, pp. 1–9, 2020, doi: 10.1038/s41598-020-74091-z.

N. I. M. Nik-Pa et al., “Combined optimization of codon usage and glycine supplementation enhances the extracellular production of a β-cyclodextrin glycosyltransferase from Bacillus sp. Nr5 upm in Escherichia coli,†Int. J. Mol. Sci., vol. 21, no. 11, 2020, doi: 10.3390/ijms21113919.

G. L. Rosano, E. S. Morales, and E. A. Ceccarelli, “New tools for recombinant protein production in Escherichia coli: A 5-year update,†Protein Sci., vol. 28, no. 8, pp. 1412–1422, 2019, doi: 10.1002/pro.3668.

S. Mahmoodi, M. Pourhassan-Moghaddam, D. W. Wood, H. Majdi, and N. Zarghami, “Current affinity approaches for purification of recombinant proteins,†Cogent Biol., vol. 5, no. 1, p. 1665406, 2019, doi: 10.1080/23312025.2019.1665406.

A. Bhatwa, W. Wang, Y. I. Hassan, N. Abraham, X. Z. Li, and T. Zhou, “Challenges Associated With the Formation of Recombinant Protein Inclusion Bodies in Escherichia coli and Strategies to Address Them for Industrial Applications,†Frontiers in Bioengineering and Biotechnology, vol. 9, no. February. pp. 1–18, 2021, doi: 10.3389/fbioe.2021.630551.

R. Agrawal, P. K. Singh, S. K. Sharma, D. V. Kamboj, A. K. Goel, and L. Singh, “Highly Expressed Recombinant SEB for Antibody Production and Development of Immunodetection System,†Indian J. Microbiol., vol. 52, no. 2, pp. 191–196, 2012, doi: 10.1007/s12088-011-0173-7.




DOI: http://dx.doi.org/10.18517/ijaseit.13.1.16754

Refbacks

  • There are currently no refbacks.


Published by INSIGHT - Indonesian Society for Knowledge and Human Development